# Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors
Canonical URL: https://biopharmsignal.com/news/PSNL/personalis-receives-medicare-coverage-for-next-personalr-for-immunotherapy-monitoring-across-late-stage-solid-tumors
Ticker: PSNL
Company: Personalis
Source: Personalis
Published: 2026-05-13 10:00 EST
Original Source URL: https://investors.personalis.com
## Summary

Expanded coverage, supported by published data from the Vall d’Hebron Institute of Oncology (VHIO), enables Medicare beneficiaries receiving immunotherapy to access ultrasensitive MRD testing to monitor treatment response and predict clinical outcomes. FREMONT, Calif.

## Article Body
Expanded coverage, supported by published data from the Vall d’Hebron Institute of Oncology (VHIO), enables Medicare beneficiaries receiving immunotherapy to access ultrasensitive MRD testing to monitor treatment response and predict clinical outcomes. FREMONT, Calif.
## Recent Company News
- 2026-06-02 10:00 EST — [Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026](https://biopharmsignal.com/news/PSNL/personalis-highlights-early-colorectal-cancer-recurrence-detection-and-ultrasensitive-mrd-performance-across-a-broad-set-of-tumor-types-at-asco-2026) — Source: Personalis
- 2026-05-26 10:00 EST — [Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium](https://biopharmsignal.com/news/PSNL/personalis-to-highlight-breadth-of-next-personalr-ultra-sensitive-ctdna-data-at-asco-2026-annual-meeting-including-podium-presentation-from-tracerx-consortium) — Source: Personalis
- 2026-05-20 10:00 EST — [Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring](https://biopharmsignal.com/news/PSNL/personalis-secures-fourth-medicare-coverage-decision-for-next-personalr-expanding-breast-cancer-coverage-to-pre-surgical-treatment-monitoring) — Source: Personalis
- 2026-05-14 20:01 EST — [Personalis to Participate in Upcoming Investor Events](https://biopharmsignal.com/news/PSNL/personalis-to-participate-in-upcoming-investor-events) — Source: Personalis
- 2026-05-13 10:00 EST — [Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors](https://biopharmsignal.com/news/PSNL/personalis-receives-medicare-coverage-for-next-personalr-for-immunotherapy-monitoring-across-late-stage-solid-tumors) — Source: Personalis
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)